Oncternal Therapeutics Past Earnings Performance
Past criteria checks 0/6
Oncternal Therapeutics's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
-19.4%
Earnings growth rate
41.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -9.9% |
| Return on equity | -131.4% |
| Net Margin | -5,029.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Oncternal Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -39 | 13 | 0 |
| 30 Sep 23 | 1 | -42 | 13 | 0 |
| 30 Jun 23 | 1 | -43 | 13 | 0 |
| 31 Mar 23 | 1 | -46 | 13 | 0 |
| 31 Dec 22 | 1 | -44 | 13 | 0 |
| 30 Sep 22 | 2 | -41 | 13 | 0 |
| 30 Jun 22 | 4 | -39 | 12 | 0 |
| 31 Mar 22 | 4 | -35 | 12 | 0 |
| 31 Dec 21 | 4 | -31 | 12 | 0 |
| 30 Sep 21 | 5 | -26 | 10 | 0 |
| 30 Jun 21 | 4 | -21 | 10 | 0 |
| 31 Mar 21 | 4 | -18 | 9 | 0 |
| 31 Dec 20 | 3 | -17 | 8 | 0 |
| 30 Sep 20 | 3 | -19 | 9 | 0 |
| 30 Jun 20 | 2 | -19 | 10 | 0 |
| 31 Mar 20 | 3 | -37 | 9 | 0 |
| 31 Dec 19 | 2 | -34 | 7 | 0 |
| 30 Sep 19 | 2 | -31 | 5 | 0 |
| 30 Jun 19 | 2 | -28 | 3 | 0 |
| 31 Mar 19 | 3 | -7 | 2 | 0 |
| 31 Dec 18 | 3 | -7 | 2 | 0 |
| 31 Dec 17 | 2 | -10 | 3 | 0 |
Quality Earnings: GTU is currently unprofitable.
Growing Profit Margin: GTU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GTU is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Accelerating Growth: Unable to compare GTU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GTU has a negative Return on Equity (-131.37%), as it is currently unprofitable.